PubMed · 12498015
Frovatriptan Vernalis.
Abstract
Vanguard (now Vernalis) has developed frovatriptan, a selective 5-HT1B/1D partial agonist licensed from GlaxoSmithKline as a potential treatment for migraine [188478], [194382], [377863].
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Hermann A M Mucke. 2002. Frovatriptan Vernalis.. https://pubmed.ncbi.nlm.nih.gov/12498015/
Cite the original work for its findings. Save a collection to share your selection of sources.